EMEA-001858-PIP02-16

  • Email
  • Help

Overview

Product details for -
Invented name-
Active substance

Liposomal combination of cytarabine and daunorubicin

Decision numberP/0200/2017
PIP numberEMEA-001858-PIP02-16
Pharmaceutical form(s)Powder for solution for infusion
Condition(s)/indication(s)

Treatment of acute myeloid leukaemia

Route(s) of administrationIntravenous use
PIP applicant

Jazz Pharmaceuticals Ireland Limited
United States
Tel. +1 6092436211
E-mail: michael.chiarella@jazzpharma.com
 

Decision typeP: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision